This is one of those questions where I wish I had a tiny bit more information about the decision-making behind electing NAC. For instance, was this breast cancer grade 3, with a high Ki-67 and ER 25% PR ngtv? Or was this patient a very borderline candidate for breast-conservation and motivated enoug...

While I agree that additional information would be helpful, would add a few comments. In NSABP B-27, patients who did not have a clinical response to AC did not benefit—in terms of pCR rate or DFS—to subsequent treatment with docetaxel (in contrast to clinical PR patients who did); and i...